Information  X 
Enter a valid email address

Company Name matching 'Bavarian Nordic A/S'

Date
Time Source
Company
Announcement
15 Aug 2019 6:51 am GNW     Bavarian Nordic A/S Bavarian Nordic Announces First Half 2019 Results
25 Jun 2019 7:46 am GNW     Bavarian Nordic A/S Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense Programs
19 Jun 2019 6:08 pm GNW     Bavarian Nordic A/S Bavarian Nordic Initiates Phase 3 Trial of Freeze-dried MVA-BN® Smallpox Vaccine
05 Jun 2019 8:11 pm GNW     Bavarian Nordic A/S Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
22 May 2019 6:51 am GNW     Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Three Months of 2019
14 May 2019 4:30 pm GNW     Bavarian Nordic A/S Bavarian Nordic to Host First Quarter 2019 Results Conference Call
28 Mar 2019 7:00 am GNW     Bavarian Nordic A/S Bavarian Nordic A/S – Notice Convening Ordinary General Meeting
21 Mar 2019 6:47 am GNW     [email protected] Bavarian Nordic Announces Annual Report 2018
21 Feb 2019 6:33 pm GNW     [email protected] Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
25 Jan 2019 10:58 am GNW     [email protected] Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
18 Jan 2019 6:15 am GNW     [email protected] Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine
21 Dec 2018 8:28 pm GNW     [email protected] Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine
09 Nov 2018 6:48 am GNW     [email protected] Bavarian Nordic Announces Interim Results for the First Nine Months of 2018
02 Nov 2018 4:30 pm GNW     [email protected] Bavarian Nordic to Host Third Quarter 2018 Results Conference Call
  1:55 pm GNW     [email protected] Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers
01 Nov 2018 1:33 pm GNW     [email protected] Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma
19 Sep 2018 6:30 am GNW     [email protected] Bavarian Nordic Delivers Smallpox Vaccine to England in Response to Current Monkeypox Cases
18 Sep 2018 6:50 pm GNW     [email protected] Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer
21 Aug 2018 6:45 am GNW     [email protected] Importance of Smallpox Vaccination Highlighted in Biopreparedness Exercise
16 Aug 2018 6:57 am GNW     [email protected] Bavarian Nordic Announces First Half 2018 Results
09 Aug 2018 4:56 pm GNW     [email protected] Bavarian Nordic Granted EUR 30 Million Loan from The European Investment Bank
08 Aug 2018 4:30 pm GNW     [email protected] Bavarian Nordic to Host First Half 2018 Results Conference Call
  1:07 pm GNW     [email protected] Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
11 Jul 2018 11:01 am GNW     [email protected] Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
01 Jun 2018 4:30 pm GNW     [email protected] Bavarian Nordic to Present at Jefferies 2018 Healthcare Conference in New York City
31 May 2018 7:00 am GNW     [email protected] Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial Officer
24 May 2018 6:42 am GNW     [email protected] Bavarian Nordic Announces Interim Results for the First Three Months of 2018
16 May 2018 10:00 pm GNW     [email protected] Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
  4:30 pm GNW     [email protected] Bavarian Nordic to Host First Quarter 2018 Results Conference Call
02 May 2018 2:34 pm GNW     [email protected] Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of Chordoma
17 Apr 2018 4:52 pm GNW     [email protected] Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held April 17, 2018
27 Mar 2018 6:20 pm GNW     [email protected] Bavarian Nordic to Present at Needham & Company's 17th Annual Healthcare Conference in New York City
26 Mar 2018 12:48 pm GNW     [email protected] Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
16 Mar 2018 12:54 pm GNW     [email protected] Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus
12 Mar 2018 6:40 am GNW     [email protected] Bavarian Nordic Announces Annual Report 2017
08 Mar 2018 1:59 pm GNW     [email protected] Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
07 Mar 2018 4:30 pm GNW     [email protected] Bavarian Nordic to Host Full Year 2017 Results Conference Call
06 Mar 2018 1:33 pm GNW     [email protected] Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
26 Feb 2018 9:39 am GNW     [email protected] Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
06 Feb 2018 5:22 pm GNW     [email protected] Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
31 Jan 2018 4:04 pm GNW     [email protected] Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen
19 Jan 2018 6:00 am GNW     [email protected] Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
21 Nov 2017 6:05 pm GNW     [email protected] Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine
09 Nov 2017 6:30 am GNW     [email protected] Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
08 Nov 2017 6:51 am GNW     [email protected] Bavarian Nordic Announces Interim Results for the First Nine Months of 2017
27 Sep 2017 9:18 pm GNW     [email protected] Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government
21 Sep 2017 9:13 am GNW     [email protected] Bavarian Nordic Provides Update on its Universal RSV Vaccine
14 Sep 2017 9:02 pm GNW     [email protected] Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer
  1:00 pm GNW     [email protected] Bavarian Nordic to Host Capital Markets Day in New York City
11 Sep 2017 8:15 am GNW     [email protected] Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress
25 Aug 2017 6:54 am GNW     [email protected] Bavarian Nordic Announces First Half 2017 Results
22 Aug 2017 5:08 pm GNW     [email protected] Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc.
21 Aug 2017 8:41 pm GNW     [email protected] Bavarian Nordic Announces Closing of Transaction with Janssen Pharmaceuticals, Inc. and Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.
18 Aug 2017 3:00 pm GNW     [email protected] Bavarian Nordic to Host First Half 2017 Results Conference Call
09 Aug 2017 7:24 pm GNW     [email protected] Bavarian Nordic Announces Subscription Price and Number of Shares to be Issued to Johnson & Johnson Innovation - JJDC, Inc.
27 Jul 2017 7:05 am GNW     [email protected] Bavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.
  7:00 am GNW     [email protected] Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis B
27 Jun 2017 1:00 pm GNW     [email protected] Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
16 Jun 2017 8:27 am GNW     [email protected] Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE
  6:30 am GNW     [email protected] Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study


Company Announcements Archive »

 
Headlines
Top categories

24-Sep-2019 07:00 AM

Economic Events - Today's Events

UK24/09/2019 11:00 CBI Industrial Order ExpectationsUS24/09/2019 14:00 HPI m/m24/09/2019 14:00 S&P/CS Composite-20 HPI y/y24/09/2019 15:00 Richmond Manufacturing Index24/09/2019 15:00 CB ...

Company finder

a d v e r t i s e m e n t